Clinical Trial Update: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results posted for omalizumab used as monotherapy and as adjunct to multi-allergen oral immunotherapy in peanut allergy and multi-food al…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multi-food Allergy
• Peanut Allergy

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Peanut Allergy, Multi-food Allergy | Phase 3 | Status: COMPLETED | Results posted: 2024-06-04